We are analyzing https://link.springer.com/article/10.1007/s00280-005-0163-8.

Title:
The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin | Cancer Chemotherapy and Pharmacology
Description:
Background: Tumour growth is dependent on angiogenesis. Antiangiogenic chemotherapy, i.e. continuous or metronomic low-dose chemotherapy, is a method for administrating cytostatics at a low and well-tolerated concentration without prolonged breaks. The target is the genetically stable endothelial cells playing a pivotal role in angiogenesis within the tumour. Different mediators could mediate the antiangiogenic effect of metronomic chemotherapy. One of these mediators could be thrombospondin (TSP). TSP is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth. This study was designed to evaluate the effects of low-dose continuous or moderate-dose bolus chemotherapy on tumour growth and on tumour expression of TSP. Materials and methods: Rats bearing a malignant prostate tumour (Dunning AT-1) not expressing TSP were treated systemically with cyclophosphamide, doxorubicin or paclitaxel and the combination of cyclophosphamide and doxorubicin. Tumour growth and body weight were measured during the treatment. CD36, one of TSP’s main receptors, was also analysed. The expression pattern of TSP-1, TSP-2 and CD36 was investigated using immunohistochemistry and Western blot analyses. Q-PCR was used to analyse TSP-1 mRNA expression. Results: Low-dose cyclophosphamide and paclitaxel re-induced the expression of TSP in the tumours. However, following a bolus dose of doxorubicin, tumours showed no expression of TSP. Both cyclophosphamide and doxorubicin treatments decreased the tumour weight by more than 60% compared with vehicle controls. When cyclophosphamide and doxorubicin were combined the tumour weight was reduced by 47%, while paclitaxel reduced the tumour weight by 18% compared to the vehicle controls. Conclusions: Systemic low-dose continuous treatment of a rat prostate cancer model with cyclophosphamide and paclitaxel induced the expression of TSP in tumour tissue and inhibited tumour growth. These findings support the hypothesis that the anti-tumour effect of low-dose metronomic chemotherapy, at least with certain chemotherapeutics, is partly mediated by induction of endogenous antiangiogenic factors.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Social Networks
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

article, pubmed, google, scholar, cancer, cas, chemotherapy, tumour, thrombospondin, angiogenesis, growth, expression, metronomic, tsp, prostate, lowdose, antiangiogenic, endothelial, tumor, continuous, damber, cyclophosphamide, res, cell, albertsson, paclitaxel, privacy, cookies, content, effect, vallbo, norrby, cells, doxorubicin, oncol, prostatic, sahlgrenska, university, publish, search, mediated, effects, weight, model, access, factor, clin, sweden, data, information,

Topics {✒️}

month download article/chapter low-dose continuous chemotherapy metronomic low-dose chemotherapy low-dose metronomic chemotherapy bone-marrow-derived endothelial moderate-dose bolus chemotherapy experimental drug-resistant cancer jan-erik damber article cancer chemotherapy fibroblast growth factor-2 low-dose continuous circulating endothelial cells endothelial progenitor cells full article pdf privacy choices/manage cookies endothelial cell progenitors tumor microenvironment contributes chemotherapy improves efficacy controlling tumour growth inhibited tumour growth increase tumor angiogenesis surrogate angiogenesis marker tumor growth suppression endostatin inhibits differentiation dose-related effects low-dose cyclophosphamide anti-tumour effect malignant prostate tumour benign prostatic hyperplasia prostatic intraepithelial neoplasia antiangiogenic tumor therapies european economic area western blot analyses sledge gw jr blood vessel maturation key functional regulators predicting metastatic abilities antiangiogenesis—drug-specific producing objective responses swedish cancer society christina vallbo metronomic paclitaxel treatment sahlgrenska university hospital conditions privacy policy metronomic chemotherapy article damber related subjects pro-apoptotic effects endogenous antiangiogenic factors combining antiangiogenic agents

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
         description:Background: Tumour growth is dependent on angiogenesis. Antiangiogenic chemotherapy, i.e. continuous or metronomic low-dose chemotherapy, is a method for administrating cytostatics at a low and well-tolerated concentration without prolonged breaks. The target is the genetically stable endothelial cells playing a pivotal role in angiogenesis within the tumour. Different mediators could mediate the antiangiogenic effect of metronomic chemotherapy. One of these mediators could be thrombospondin (TSP). TSP is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth. This study was designed to evaluate the effects of low-dose continuous or moderate-dose bolus chemotherapy on tumour growth and on tumour expression of TSP. Materials and methods: Rats bearing a malignant prostate tumour (Dunning AT-1) not expressing TSP were treated systemically with cyclophosphamide, doxorubicin or paclitaxel and the combination of cyclophosphamide and doxorubicin. Tumour growth and body weight were measured during the treatment. CD36, one of TSP’s main receptors, was also analysed. The expression pattern of TSP-1, TSP-2 and CD36 was investigated using immunohistochemistry and Western blot analyses. Q-PCR was used to analyse TSP-1 mRNA expression. Results: Low-dose cyclophosphamide and paclitaxel re-induced the expression of TSP in the tumours. However, following a bolus dose of doxorubicin, tumours showed no expression of TSP. Both cyclophosphamide and doxorubicin treatments decreased the tumour weight by more than 60% compared with vehicle controls. When cyclophosphamide and doxorubicin were combined the tumour weight was reduced by 47%, while paclitaxel reduced the tumour weight by 18% compared to the vehicle controls. Conclusions: Systemic low-dose continuous treatment of a rat prostate cancer model with cyclophosphamide and paclitaxel induced the expression of TSP in tumour tissue and inhibited tumour growth. These findings support the hypothesis that the anti-tumour effect of low-dose metronomic chemotherapy, at least with certain chemotherapeutics, is partly mediated by induction of endogenous antiangiogenic factors.
         datePublished:2005-12-07T00:00:00Z
         dateModified:2005-12-07T00:00:00Z
         pageStart:354
         pageEnd:360
         sameAs:https://doi.org/10.1007/s00280-005-0163-8
         keywords:
            Continuous chemotherapy
            Metronomic chemotherapy
            Thrombospondin
            Angiogenesis
            Tumour growth
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig4_HTML.jpg
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jan-Erik Damber
               affiliation:
                     name:Göteborg University, Sahlgrenska University Hospital
                     address:
                        name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Christina Vallbo
               affiliation:
                     name:Göteborg University, Sahlgrenska University Hospital
                     address:
                        name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Per Albertsson
               affiliation:
                     name:Göteborg University
                     address:
                        name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bo Lennernäs
               affiliation:
                     name:Göteborg University
                     address:
                        name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Klas Norrby
               affiliation:
                     name:Göteborg University
                     address:
                        name:Department of Pathology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
      description:Background: Tumour growth is dependent on angiogenesis. Antiangiogenic chemotherapy, i.e. continuous or metronomic low-dose chemotherapy, is a method for administrating cytostatics at a low and well-tolerated concentration without prolonged breaks. The target is the genetically stable endothelial cells playing a pivotal role in angiogenesis within the tumour. Different mediators could mediate the antiangiogenic effect of metronomic chemotherapy. One of these mediators could be thrombospondin (TSP). TSP is a potent inhibitor of angiogenesis and might therefore be important in controlling tumour growth. This study was designed to evaluate the effects of low-dose continuous or moderate-dose bolus chemotherapy on tumour growth and on tumour expression of TSP. Materials and methods: Rats bearing a malignant prostate tumour (Dunning AT-1) not expressing TSP were treated systemically with cyclophosphamide, doxorubicin or paclitaxel and the combination of cyclophosphamide and doxorubicin. Tumour growth and body weight were measured during the treatment. CD36, one of TSP’s main receptors, was also analysed. The expression pattern of TSP-1, TSP-2 and CD36 was investigated using immunohistochemistry and Western blot analyses. Q-PCR was used to analyse TSP-1 mRNA expression. Results: Low-dose cyclophosphamide and paclitaxel re-induced the expression of TSP in the tumours. However, following a bolus dose of doxorubicin, tumours showed no expression of TSP. Both cyclophosphamide and doxorubicin treatments decreased the tumour weight by more than 60% compared with vehicle controls. When cyclophosphamide and doxorubicin were combined the tumour weight was reduced by 47%, while paclitaxel reduced the tumour weight by 18% compared to the vehicle controls. Conclusions: Systemic low-dose continuous treatment of a rat prostate cancer model with cyclophosphamide and paclitaxel induced the expression of TSP in tumour tissue and inhibited tumour growth. These findings support the hypothesis that the anti-tumour effect of low-dose metronomic chemotherapy, at least with certain chemotherapeutics, is partly mediated by induction of endogenous antiangiogenic factors.
      datePublished:2005-12-07T00:00:00Z
      dateModified:2005-12-07T00:00:00Z
      pageStart:354
      pageEnd:360
      sameAs:https://doi.org/10.1007/s00280-005-0163-8
      keywords:
         Continuous chemotherapy
         Metronomic chemotherapy
         Thrombospondin
         Angiogenesis
         Tumour growth
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0163-8/MediaObjects/280_2005_163_Fig4_HTML.jpg
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jan-Erik Damber
            affiliation:
                  name:Göteborg University, Sahlgrenska University Hospital
                  address:
                     name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Christina Vallbo
            affiliation:
                  name:Göteborg University, Sahlgrenska University Hospital
                  address:
                     name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Per Albertsson
            affiliation:
                  name:Göteborg University
                  address:
                     name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bo Lennernäs
            affiliation:
                  name:Göteborg University
                  address:
                     name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Klas Norrby
            affiliation:
                  name:Göteborg University
                  address:
                     name:Department of Pathology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:58
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Göteborg University, Sahlgrenska University Hospital
      address:
         name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
         type:PostalAddress
      name:Göteborg University, Sahlgrenska University Hospital
      address:
         name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
         type:PostalAddress
      name:Göteborg University
      address:
         name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
         type:PostalAddress
      name:Göteborg University
      address:
         name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
         type:PostalAddress
      name:Göteborg University
      address:
         name:Department of Pathology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jan-Erik Damber
      affiliation:
            name:Göteborg University, Sahlgrenska University Hospital
            address:
               name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Christina Vallbo
      affiliation:
            name:Göteborg University, Sahlgrenska University Hospital
            address:
               name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
               type:PostalAddress
            type:Organization
      name:Per Albertsson
      affiliation:
            name:Göteborg University
            address:
               name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
               type:PostalAddress
            type:Organization
      name:Bo Lennernäs
      affiliation:
            name:Göteborg University
            address:
               name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
               type:PostalAddress
            type:Organization
      name:Klas Norrby
      affiliation:
            name:Göteborg University
            address:
               name:Department of Pathology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
      name:Department of Urology, Institute of Surgical Sciences, Sahlgrenska Academy, Göteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
      name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
      name:Department of Oncology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
      name:Department of Pathology, Sahlgrenska Academy, Göteborg University, Goteborg, Sweden
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(100)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.85s.

LINK . SPRINGER . COM {}